These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 27289488)

  • 41. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.
    Carrier M; Le Gal G; Cho R; Tierney S; Rodger M; Lee AY
    J Thromb Haemost; 2009 May; 7(5):760-5. PubMed ID: 19245418
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
    Jacobs BN; Cain-Nielsen AH; Jakubus JL; Mikhail JN; Fath JJ; Regenbogen SE; Hemmila MR
    J Trauma Acute Care Surg; 2017 Jul; 83(1):151-158. PubMed ID: 28426561
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Bates SM; Greer IA; Middeldorp S; Veenstra DL; Prabulos AM; Vandvik PO
    Chest; 2012 Feb; 141(2 Suppl):e691S-e736S. PubMed ID: 22315276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.
    Raskob G; Büller H; Prins M; Segers A; Shi M; Schwocho L; van Kranen R; Mercuri M;
    J Thromb Haemost; 2013 Jul; 11(7):1287-94. PubMed ID: 23574579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of venous thromboembolism in pregnant patients with a history of venous thromboembolic disease: A retrospective cohort study.
    Lazo-Langner A; Al-Ani F; Weisz S; Rozanski C; Louzada M; Kovacs J; Kovacs MJ
    Thromb Res; 2018 Jul; 167():20-25. PubMed ID: 29772489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pregnancy-Related Venous Thromboembolism.
    Armstrong EM; Bellone JM; Hornsby LB; Treadway S; Phillippe HM
    J Pharm Pract; 2014 Jun; 27(3):243-52. PubMed ID: 24742932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preventing postpartum venous thromboembolism: A call to action to reduce undue maternal morbidity and mortality.
    Andrew L; Ní Áinle F; Blondon M; Rodger MA; Skeith L
    Thromb Res; 2020 Sep; 193():190-197. PubMed ID: 32738644
    [TBL] [Abstract][Full Text] [Related]  

  • 49. What is the effect of low-molecular weight heparin for venous thromboembolism prophylaxis compared with mechanical methods, on the occurrence of hemorrhagic and venous thromboembolic complications in patients with intracerebral hemorrhage? A critically appraised topic.
    O'Carroll CB; Capampangan DJ; Aguilar MI; Bravo TP; Hoffman-Snyder CR; Wingerchuk DM; Wellik KE; Demaerschalk BM
    Neurologist; 2011 Jul; 17(4):232-5. PubMed ID: 21712672
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
    Lee AY; Bauersachs R; Janas MS; Jarner MF; Kamphuisen PW; Meyer G; Khorana AA;
    BMC Cancer; 2013 Jun; 13():284. PubMed ID: 23764005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study.
    Kwiatt ME; Patel MS; Ross SE; Lachant MT; MacNew HG; Ochsner MG; Norwood SH; Speier L; Kozar R; Gerber JA; Rowell S; Krishnakumar S; Livingston DH; Manis G; Haan JM
    J Trauma Acute Care Surg; 2012 Sep; 73(3):625-8. PubMed ID: 22929493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Compliance with the 2009 Royal College of Obstetricians and Gynaecologists guidelines for venous thromboembolic disease prophylaxis in pregnancy and postpartum period in Uruguay.
    Grille S; Vitureira G; Morán R; Retamosa L; Alonso V; Gómez LM; Quartara F; Feldman F; López V; Turcatti P; Castro V; Sosa L; Guillermo C; Díaz L; Stevenazzi M
    Blood Coagul Fibrinolysis; 2018 Apr; 29(3):252-256. PubMed ID: 29369082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
    Fuentes HE; Oramas DM; Paz LH; Casanegra AI; Mansfield AS; Tafur AJ
    Thromb Res; 2017 Jun; 154():28-34. PubMed ID: 28402864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thromboprophylaxis with low-molecular-weight heparin after cesarean delivery.
    Blondon M; Perrier A; Nendaz M; Righini M; Boehlen F; Boulvain M; De Moerloose P
    Thromb Haemost; 2010 Jan; 103(1):129-37. PubMed ID: 20062923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not affect outcomes in pregnant patients with venous thromboembolism.
    McDonnell BP; Glennon K; McTiernan A; O'Connor HD; Kirkham C; Kevane B; Donnelly JC; Ni Áinle F
    J Thromb Thrombolysis; 2017 Jan; 43(1):105-111. PubMed ID: 27517381
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review.
    Ribic C; Lim W; Cook D; Crowther M
    J Crit Care; 2009 Jun; 24(2):197-205. PubMed ID: 19327323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.